Determination of bioequivalence for drugs with narrow therapeutic index: Reduction of the regulatory burden

Laszlo Endrenyi, L. Tóthfalusi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The US Food and Drug Administration (FDA) has recently suggested that the bioequivalence (BE) for products of drugs with narrow therapeutic indices (NTI) be assessed by the approach of referencescaled average BE (SABE). Subsequently, in December, 2012, the FDA issued draft guidances for the comparison of products of warfarin sodium and of tacrolimus. The guidances expect that 4-period studies be performed, that the results be evaluated by SABE, and that the analysis include also unscaled average BE as well as the comparison of the estimated within-subject variations (sW) of the test and reference drug products. This communication discusses the new guidances and suggests considerations to reduce the regulatory burden. It is demonstrated that SABE could be applied when the within-subject variation of the reference product is not higher than 21.42%. Beyond this variation, the BE limits would remain 80% to 125%, as usual. No further testing by unscaled average BE is needed. It is also suggested that a comparison of the within-subject variations of the two drug products although interesting for both NTI and other drugs, is not essential for the determination of BE. In addition, when the within-subject variabilities are low then their ratio depends mainly on the nonproduct dependent factors. Moreover, introduction of an additional test would affect the probabilities involved in the primary comparison of the two means. Therefore, the test of comparing variances is not needed and replicate measurements of the test formulation need not be performed. Alternative considerations and approaches, including the use of partial AUC's, are suggested for the determination of BE for NTI drugs.

Original languageEnglish
Pages (from-to)676-682
Number of pages7
JournalJournal of Pharmacy and Pharmaceutical Sciences
Volume16
Issue number5
Publication statusPublished - Nov 22 2013

Fingerprint

Therapeutic Equivalency
Pharmaceutical Preparations
United States Food and Drug Administration
Therapeutics
Tacrolimus
Warfarin
Area Under Curve

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Determination of bioequivalence for drugs with narrow therapeutic index : Reduction of the regulatory burden. / Endrenyi, Laszlo; Tóthfalusi, L.

In: Journal of Pharmacy and Pharmaceutical Sciences, Vol. 16, No. 5, 22.11.2013, p. 676-682.

Research output: Contribution to journalArticle

@article{e12761bf486746e38a08c84adb47a48c,
title = "Determination of bioequivalence for drugs with narrow therapeutic index: Reduction of the regulatory burden",
abstract = "The US Food and Drug Administration (FDA) has recently suggested that the bioequivalence (BE) for products of drugs with narrow therapeutic indices (NTI) be assessed by the approach of referencescaled average BE (SABE). Subsequently, in December, 2012, the FDA issued draft guidances for the comparison of products of warfarin sodium and of tacrolimus. The guidances expect that 4-period studies be performed, that the results be evaluated by SABE, and that the analysis include also unscaled average BE as well as the comparison of the estimated within-subject variations (sW) of the test and reference drug products. This communication discusses the new guidances and suggests considerations to reduce the regulatory burden. It is demonstrated that SABE could be applied when the within-subject variation of the reference product is not higher than 21.42{\%}. Beyond this variation, the BE limits would remain 80{\%} to 125{\%}, as usual. No further testing by unscaled average BE is needed. It is also suggested that a comparison of the within-subject variations of the two drug products although interesting for both NTI and other drugs, is not essential for the determination of BE. In addition, when the within-subject variabilities are low then their ratio depends mainly on the nonproduct dependent factors. Moreover, introduction of an additional test would affect the probabilities involved in the primary comparison of the two means. Therefore, the test of comparing variances is not needed and replicate measurements of the test formulation need not be performed. Alternative considerations and approaches, including the use of partial AUC's, are suggested for the determination of BE for NTI drugs.",
author = "Laszlo Endrenyi and L. T{\'o}thfalusi",
year = "2013",
month = "11",
day = "22",
language = "English",
volume = "16",
pages = "676--682",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
issn = "1482-1826",
publisher = "Canadian Society for Pharmaceutical Sciences",
number = "5",

}

TY - JOUR

T1 - Determination of bioequivalence for drugs with narrow therapeutic index

T2 - Reduction of the regulatory burden

AU - Endrenyi, Laszlo

AU - Tóthfalusi, L.

PY - 2013/11/22

Y1 - 2013/11/22

N2 - The US Food and Drug Administration (FDA) has recently suggested that the bioequivalence (BE) for products of drugs with narrow therapeutic indices (NTI) be assessed by the approach of referencescaled average BE (SABE). Subsequently, in December, 2012, the FDA issued draft guidances for the comparison of products of warfarin sodium and of tacrolimus. The guidances expect that 4-period studies be performed, that the results be evaluated by SABE, and that the analysis include also unscaled average BE as well as the comparison of the estimated within-subject variations (sW) of the test and reference drug products. This communication discusses the new guidances and suggests considerations to reduce the regulatory burden. It is demonstrated that SABE could be applied when the within-subject variation of the reference product is not higher than 21.42%. Beyond this variation, the BE limits would remain 80% to 125%, as usual. No further testing by unscaled average BE is needed. It is also suggested that a comparison of the within-subject variations of the two drug products although interesting for both NTI and other drugs, is not essential for the determination of BE. In addition, when the within-subject variabilities are low then their ratio depends mainly on the nonproduct dependent factors. Moreover, introduction of an additional test would affect the probabilities involved in the primary comparison of the two means. Therefore, the test of comparing variances is not needed and replicate measurements of the test formulation need not be performed. Alternative considerations and approaches, including the use of partial AUC's, are suggested for the determination of BE for NTI drugs.

AB - The US Food and Drug Administration (FDA) has recently suggested that the bioequivalence (BE) for products of drugs with narrow therapeutic indices (NTI) be assessed by the approach of referencescaled average BE (SABE). Subsequently, in December, 2012, the FDA issued draft guidances for the comparison of products of warfarin sodium and of tacrolimus. The guidances expect that 4-period studies be performed, that the results be evaluated by SABE, and that the analysis include also unscaled average BE as well as the comparison of the estimated within-subject variations (sW) of the test and reference drug products. This communication discusses the new guidances and suggests considerations to reduce the regulatory burden. It is demonstrated that SABE could be applied when the within-subject variation of the reference product is not higher than 21.42%. Beyond this variation, the BE limits would remain 80% to 125%, as usual. No further testing by unscaled average BE is needed. It is also suggested that a comparison of the within-subject variations of the two drug products although interesting for both NTI and other drugs, is not essential for the determination of BE. In addition, when the within-subject variabilities are low then their ratio depends mainly on the nonproduct dependent factors. Moreover, introduction of an additional test would affect the probabilities involved in the primary comparison of the two means. Therefore, the test of comparing variances is not needed and replicate measurements of the test formulation need not be performed. Alternative considerations and approaches, including the use of partial AUC's, are suggested for the determination of BE for NTI drugs.

UR - http://www.scopus.com/inward/record.url?scp=84888397284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888397284&partnerID=8YFLogxK

M3 - Article

C2 - 24393551

AN - SCOPUS:84888397284

VL - 16

SP - 676

EP - 682

JO - Journal of Pharmacy and Pharmaceutical Sciences

JF - Journal of Pharmacy and Pharmaceutical Sciences

SN - 1482-1826

IS - 5

ER -